Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Alvotech Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 6-K Quarterly results
10/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair®"
08/01/2023 6-K Quarterly results
07/24/2023 6-K Quarterly results
07/24/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/24/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/21/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/14/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
07/14/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
07/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Master License and Supply Agreement by and between Alvotech and Mercury Pharma Group Limited (trading as Advanz Pharma Holdings)",
"Termination Agreement (Vedolizumab) by and between Alvotech and STADA Arzneimittel AG",
"Termination Agreement (Golimumab) by and between Alvotech and STADA Arzneimittel AG",
"Termination Agreement (Denosumab) by and between Alvotech and STADA Arzneimittel AG",
"Master License and Supply Agreement by and between Alvotech and Mercury Pharma Group Limited (trading as Advanz Pharma Holdings)"
06/29/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/29/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02 REYKJAVIK, Iceland, June 28, 2023 - Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug Administration has issued a complete response letter for Alvotech's second Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira ® . As the second of two BLAs submitted for AVT02, this BLA contained data to support approval as a high-concentration biosimilar and additional information to support the interchangeability designation. The CRL noted that certain deficiencies, which were conveyed following the FDA's reinspection of the company's Reykjavik facility t..."
06/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara ®"
06/06/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"2023 AGM Minutes",
"Announcement of the results of the 2023 AGM",
"Amended and restated articles of association of Alvotech",
"Announcement Granting of Stock Options"
05/24/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe"
05/19/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update"
05/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Convening notice to the Annual and Extraordinary General Meeting of Shareholders",
"Convening notice to the Annual and Extraordinary General Meeting of Shareholders",
"Proxy Card",
"Proxy Card",
"Proxy Card"
05/04/2023 6-K Quarterly results
04/14/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/14/2023 6-K Quarterly results
03/28/2023 6-K Quarterly results
03/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/13/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/01/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update",
"Corporate Governance Report",
"ESG Report"
02/14/2023 SC 13G Oaktree Acquisition Holdings II, L.P. reports a 5.9% stake in Alvotech
02/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/10/2023 6-K Quarterly results
02/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy